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Systemic inflammatory rheumatic diseases are considered as autoimmune diseases, meaning that the balance between recognition
of pathogens and avoidance of self-attack is impaired and the immune system attacks and destroys its own healthy tissue. Treatment
with conventional DiseaseModifying Antirheumatic Drugs (DMARDs) and/or Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
is often associated with various adverse reactions due to unspecific and toxic properties of those drugs. Although biologic drugs
have largely improved the outcome in many patients, such drugs still pose significant problems and fail to provide a solution to all
patients.Therefore, development of more effective treatments and improvements in early diagnosis of rheumatic diseases are badly
needed in order to increase patient’s functioning and quality of life. The reversible nature of epigenetic mechanisms offers a new
class of drugs that modulate the immune system and inflammation. In fact, epigenetic drugs are already in use in some types of
cancer or cardiovascular diseases. Therefore, epigenetic-based therapeutics that control autoimmunity and chronic inflammatory
process have broad implications for the pathogenesis, diagnosis, and management of rheumatic diseases. This review summarises
the latest information about potential therapeutic application of epigenetic modification in targeting immune abnormalities and
inflammation of rheumatic diseases.
1. Autoimmune Rheumatic Diseases
Systemic autoimmune rheumatic diseases are characterised
by pain and chronic joint inflammation. There are more
than 200 different conditions that are labelled as rheumatic
diseases including rheumatic arthritis, systemic sclerosis,
systemic lupus erythematosus, psoriatic arthritis, ankylosing
spondylitis, and Sjogren syndrome. Moreover, autoimmune
rheumatic diseases share many common features, which
makes themdifficult to differentiate within the group. Indeed,
up to 50 percent of patients with autoimmune rheumatic dis-
eases cannot be easily categorised with a specific disorder in
the first 12 months of follow-up [1].
One of the major characteristics of rheumatic diseases
is chronic inflammation and autoimmunity, which conse-
quently leads to tissue destruction and reduces patients’
mobility. Immune cells play a key role in inflammation due
to involvement in initiation and maintenance of the chronic
inflammatory stages. In particular, circulating monocytes
that may differentiate towards macrophages or dendritic cells
are able to produce proinflammatory cytokines including
interleukin-1 (IL-1), IL-6, IL-8, and tumour necrosis factor-
𝛼 (TNF-𝛼) [2]. Monocytes are also responsible for the pro-
duction of inflammatorymediators including reactive oxygen
species (ROS) and cyclooxygenase-2 (COX-2) [3]. COX-2
is a key enzyme in prostaglandins biosynthesis driving the
inflammatory response. Monocytes can produce chemokines
which attract T and B cells for the secretion of proin-
flammatory cytokines. Activated B cells are able to present
autoantigens and produce autoantibodies maintaining the
inflammatory process leading to tissue destruction. The
presence of autoantibodies is a hallmark of autoimmune
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rheumatic diseases [4]. Also, a subset of helper CD4+ T cells,
Th17, is reported to be involved in rheumatic pathogenesis
[5]. Th17 cells are characterised by production of IL-17.
This interleukin is a potent proinflammatory cytokine that
amplifies ongoing inflammation by induction of TNF-𝛼, IL-
1𝛽, and IL-6 inmacrophages as well as of other cell types such
as keratinocytes, fibroblasts, and synoviocytes. Fibroblast-
like synoviocytes (FLS) located inside joints in the synovium
also play a key role in pathogenesis of rheumatic diseases due
to their production of proinflammatory cytokines, adhesion
molecules, and matrix proteases contributing to cartilage
destruction. Rheumatoid FLS develop a unique autoaggres-
sive phenotype that increases invasiveness into the extracel-
lular matrix, promotes inflammatory cell recruitment, and
elevates production of COX-2. NSAIDs are widely used anti-
inflammatory agents that act through the inhibition of the
COX enzymes. Although COX-inhibitors lead to reduced
synthesis of prostaglandins at the site of inflammation, sup-
pression of gastrointestinal or renal prostaglandins synthesis
is associated with mechanism-based toxicities. This limits
the usefulness of these otherwise potent drugs. In addition,
COX-2 inhibitors have been found to increase the risk
of myocardial infarction. Thus, finding new agents which
will specifically block inflammation may provide therapeutic
opportunities in immune-mediated rheumatic diseases.
2. Overview on Epigenome-Influencing Drugs
Epigenetics is defined as reversible and heritable changes
in gene function without alteration of the underlying DNA
sequence itself [6]. Epigenetic mechanisms are sensitive to
external stimuli, bridging the gap between environmental
and genetic factors. In particular,monozygotic (MZ) twins do
not show complete concordance for many complex diseases.
MZ discordance rates for autoimmune diseases are 20–80
percent, indicating a substantial role of epigenetic factors in
the development of these disorders [7, 8]. Indeed, it has been
reported that epigenetic mechanisms mediate development
of chronic inflammation by modulating the expression of
proinflammatory cytokines including TNF-𝛼, IL-6, and IL-
1 and induction of COX-2 and transcription factor NF-𝜅B.
These molecules are constitutively produced by a variety of
immune cells under chronic inflammatory conditions, which
consequently leads to the development of many diseases
including cancer, cardiovascular diseases, or autoimmune
rheumatic disorders.
3. Noncoding RNA
Three main epigenetic mechanisms have been described
including noncoding RNA species, DNA methylation, and
histone modification. The first group of noncoding RNAs
includes microRNA (miRNA) and long noncoding RNA
(lncRNA). MicroRNAs (miRNAs) are endogenous, single-
stranded RNAs of 19–25 nucleotides in length which can
negatively regulate gene expression on posttranscriptional
level. In particular, miRNA can hybridise to 3–8 nucleotides
within 3󸀠-untranslated region (3󸀠UTR) of target messenger
RNA (mRNA) referred to as “seed sequence” [9]. The
Table 1: FDA-approved epigenetic drugs.
Drug Epigenetic effect Clinical trial
Miravirsen Neutralisation of miRNA-122 Phase II [13]
MRX34 Ectopic expression of miRNA-34 Phase I [9]
Azacitidine
(Vidaza) DNA methyltransferase inhibitor Phase III [15]
Decitabine
(Dacogen) DNA methyltransferase inhibitor Phase III [17]
Vorinostat
(Zolinza) Pan-HDAC inhibitor Phase II [24]
formation of such miRNA-mRNA duplexes leads to mRNA
degradation or translational repression. miRNAs have been
studied extensively due to their role in regulation of almost
every cellular process. It is known that miRNAs can act as
a fine-tuner of gene expression and can negatively regulate
approximately 30 percent of human protein-coding genes
[10]. In addition,miRNAs are attractive as potential biomark-
ers. Some of miRNAs have been already tested in preclinical
studies that aimed to treat cancer including lung, prostate,
or leukemia [11]. Interestingly, randomised, phase IIa, double
blind clinical trial (test numberNCT01200420) has been con-
ducted to treat hepatitis C virus (HCV) using locked nucleic
acid inhibitor of miRNA-122 (Table 1). miRNA-122 is crucial
for viral replication in hepatocytes; thus the reintroduction of
miRNA-122 inhibitor significantly reduced virus replication
[12, 13]. Recent phase I clinical trial has also tested the
drug called MRX34. MRX34 is a double-stranded miRNA-
34 encapsulated in liposomal nanoparticles. miRNA-34a
represses the expression of more than 20 oncogenes which
results in inhibition cancer cell viability, stemness, metastasis,
or chemoresistance. Thus, MRX34 is widely tested in solid
tumours and hematological malignancies [9]. Many studies
have also shown the role of lncRNA in diverse cellular pro-
cesses. lncRNAs are non-protein-coding transcripts longer
than 200 nucleotides regulating gene expression. However,
the exact functional roles and mechanisms of lncRNAs are
still unclear.
4. DNA Methylation
Another mechanism of epigenetic changes is DNA methyla-
tion induced by a highly conserved family of DNA methyl-
transferases (DNMTs). DNMT1 is the most abundant DNA
methyltransferase in mammalian cells [14]. The insertion of
methyl group to cytosine at the carbon 5 position leads to
structural changes in chromatin and ismostly associatedwith
gene silencing. In humans, methylation mainly occurs when
cytosine is followed by guanine and is linked with phosphate
called CpG islands. Approximately 1 percent of the genome
consists of CpG islands [11]. Also, it is reported that roughly
60–70 percent of human genes are linked to promoter CpG
islands which suggests that methylation of CpG island is
an important regulatory mechanism of gene expression [12].
It has been shown that vitamin B12 rich diet (B vitamins
acted as methyl donors) in agouti mouse model prevented
from development of inflammation mediated diabetes and
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cancer. In contrast,micewhich did not receive vitaminBwere
predisposed for these diseases [14]. Therefore, methylation
plays a key role in physiological conditions and the alteration
in DNA methylation signature can have impact on disease
development. One of the Food and Drug Administration-
(FDA-) approved drugs inhibiting DNA methylation is 5󸀠-
azacytidine (commercial name Vidaza). This drug has been
already used in phase III randomised, controlled trial to
treat myelodysplastic syndrome and leukemia [15]. Similar
inhibitory effect on DNA methyltransferases has the 5-aza-
2󸀠-deoxycytidine or 5󸀠-AZA (knownunder commercial name
Decitabine), which is used to treat many types of cancer and
the myelodysplastic syndrome [16, 17]. DNA hydroxymethy-
lation is also epigeneticmodificationmediated by Ten-Eleven
Translocation (TET) family proteins which were discovered
relatively recently [18]. TET enzymes are dioxygenases capa-
ble of oxidizing the methyl group of 5-methylcytosine (5mC)
and converting 5mC into 5-hydroxymethylcytosine (5hmC),
which results in DNA demethylation. It has been shown
that the increased expression of TET1–TET3 enzymes in
monocytes and TET2 in T cells leads to aberrant global DNA
hydroxymethylation of early RA patients [19]. Interestingly,
treatment with methotrexate partially reduces the DNA
hydroxymethylation level. Indirect TET inhibition induced
by AGI-5198 compound leads to growth suppression and
promotes differentiation of glioma cells [20]. Similarly, HMS-
101 inhibitor limits the growth of acute myeloid leukemia
cells suggesting potential therapeutic application of TET
inhibitors in cancer and also in rheumatic diseases [21].
5. Histone Modification
Another epigenetic phenomenon is histone modification.
This modification alters the electrostatic charge of the
histones resulting in conformational changes in protein
binding sites and facilitating or blocking DNA accessibil-
ity. Histone modifications can be mostly represented by
acetylation, methylation, phosphorylation, ubiquitination,
ribosylation, citrullination, biotinylation, and sumoylation
of histone N-terminal tail domains and also core domains
[22]. It is believed that the histone acetylation is usually
associated with increased binding of transcription factors
to nucleosomal DNA and facilitates transcription initiation,
whereas histone methylation can either activate or repress
gene expression. Acetylation removes the positive charge on
the histones and reduces the interaction between histones
and negatively charged phosphate groups on DNA [23].
Therefore, the condensed heterochromatin is transformed
into a more relaxed euchromatin that is associated with
greater levels of gene transcription. Vorinostat (also known as
suberanilohydroxamic acid, SAHA) has been shown to bind
to the active site of histone deacetylases (HDACs). HDACs
catalyse the removal of acetyl group from lysine residue.
Inhibition of HDACs by Vorinostat leads to accumulation
of hyperacetylated histones. This drug was the first histone
deacetylase inhibitor to be approved by FDA (2006) to treat
cutaneous T cell lymphoma with substantial response rates
over 30 percent in patients [24]. Unlike in the cancer field,
there is still no epigenetics-based drug on the market to
treat rheumatic disorders. Finding new agents is greatly
needed, because the economic burden of rheumatic diseases
is substantial.Their cost is estimated at more than 200 billion
Euros per year in Europe and they are the most expensive of
all diseases for the European health care systems [25]. This
review highlights the impact of chronic inflammation and
immune disability on globally disturbed DNA methylation
pattern, aberrant histone modification’ profile, and divergent
miRNA signature that is observed in autoimmune rheumatic
diseases. However, it is a chicken or egg dilemma and it needs
to be further investigated to find out whether inflammation
triggers epigenetic changes or epigenetic alteration drives
inflammation. Epigenome-influencing drugsmay have future
impact on diagnosis and/or therapeutics of rheumatic dis-
eases. Epigenetic mechanisms, which modify immune cells
and fibroblasts in rheumatic diseases, are depicted in Figure 1.
6. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is the most common inflamma-
tory joint disease which affects approximately 1% of the pop-
ulation worldwide with unknown etiology. RA is a chronic
autoimmune inflammatory condition which is characterised
by an influx of inflammatory cells from the blood stream
into the synovial membrane or synovial fluid. Such influx
of immune cells producing inflammatory cytokines results
in progressive erosion of articular cartilage. Phagocytes,
B cells, and T cells are the most prominent cells in the
rheumatoid synovium. Macrophages along with granulo-
cytes are an important source of proinflammatory cytokines,
chemokines, and reactive oxygen species (ROS) that accom-
pany inflammatory processes [4].On the other hand, antigen-
specific B cells are involved in autoantigens presentation to
T cells and in production of autoantibodies, which mediates
in joint destruction. In addition, the presence of ectopic
follicular structures in chronically inflamed tissues resem-
bling germinal centres provides strong evidence of ongoing
immune reactions [26]. Recent studies have indicated that
miRNA plays a critical role in pathogenesis of RA. Raj and
Mufti showed that miRNA-346 regulates TNF-𝛼 synthesis
(one of the major proinflammatory cytokines involved in the
pathogenesis of RA) in LPS stimulated synovial fibroblasts
[15]. The level of miRNA-146a is significantly upregulated
in CD4+ T cell subset and positively correlates with TNF-
𝛼 concentration in RA patients [16, 17]. Also, the level of
miRNA-150 is elevated in IL-17 producing T cells [27]. In
contrast, Zhang et al. reported that miRNA-23b inhibits IL-
17-associated autoimmune inflammation by targeting TGF-
𝛽 binding protein 2 (TAB2) and TAB3 [18]. Emerging
evidence revealed that lncRNAs have various expression in
autoimmune diseases. It has been shown that adalimumab
(anti-TNF-𝛼 antibody) and tocilizumab (anti-IL-6R anti-
body) treated RA patients have differential expression of 85
lncRNAs inCD14+monocytes [28]. Similarly, Song et al. have
shown elevated expression level of lncRNAs called Hotair in
PBMC and serum exosome, suggesting that lncRNAs could
be used as potential biomarkers for diagnosing RA [29],
while overexpression of Hotair by introduction of lentiviral
construct results in decreased expression of MMP-2 and
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Figure 1: Epigenetic agents modulating immune response in rheumatic diseases including RA, SSc, SLE, AS, and PsA. Schematic of the
epigenetic modulations represented by DNA methylation, histone modification, and RNA interference influencing immune cells (B cells, T
cells, and monocytes) and fibroblasts. DNA methylation refers to covalent addition of a methyl group to the 5-position of the cytosine ring,
which can be inhibited by 5󸀠-AZA. 5󸀠-AZA induces DNA hypomethylation and drives differential gene expression.Histone modifications are
reversible and site-specific histone alterations including acetylation (Acet), methylation (Meth), phosphorylation (Phosph), or ubiquitination
(Ubi). Histonemethylation or acetylation can be either activated by apicidin andTSAor inhibited byDZNep and curcumin.miRNA inhibition
is a formation of miRNA-mRNA duplexes in the position of 3󸀠UTR.This leads gene silencing (genes in black) by specific miRNAs (in red).
MMP-13 in FLS from RA patients. DNA methylation pattern
is also impaired in RA affecting immune-related genes and
consequently influencing immune responses. In particular,
global DNAhypomethylation is observed in peripheral blood
mononuclear cells (PBMCs) derived from RA patients [30].
It has been shown that hypomethylated promoter region of
chemokine CXCL12 leads to increasedMMPs expression and
joint destruction in RA patients [31]. Similarly, the methy-
lation levels of IL-6 promoter in PBMCs was significantly
lower in RA patients than those in controls [32]. In contrast,
gene coding for dual specific phosphate 22 (DUSP22) is
hypermethylated in T cells of RA and in Sjogren’s syndrome
patients [33, 34]. DUSP22 is a tyrosine phosphatase which
negatively regulates the IL-6 transcription factor STAT3. It is
known that IL-6 plays a pivotal role in chronic inflammation
in autoimmune diseases [35]. Another group has identified
that the promoter of anti-inflammatory cytokine IL-10 is
hypermethylated in four different regions of CpG site [36].
The level of IL-10 which is mainly produced by monocytes
and T reg cells is reduced in RA. It has been shown that
PBMCs treated with 5󸀠-AZA have increased production of
IL-10. This suggests that specific demethylation of IL-10
promoter induced by 5󸀠-AZA can prevent development of
RA by induction of anti-inflammatory IL-10 and suppression
of immune responses. It has been also found that alteration
in histone modification can contribute to RA development.
The balance of histone acetylase (HAT) versus HDAC is
strongly shifted towards chronic histone hyperacetylation in
RApatients [37].This consequently leads to proinflammatory
genes expression including IL-6 and IL-8. Indeed, the level of
histone H3 acetylation in the IL-6 promoter is significantly
elevated in RA synoviocytes resulting in enhanced IL-6
secretion and joint destruction [38]. Surprisingly, treatment
with curcumin abrogated H3 acetylation and reduced IL-
6 secretion which suggests that epigenetic mechanisms are
implicated in targeting RA pathogenesis.
7. Systemic Sclerosis
Systemic sclerosis (SSc) is an autoimmune connective tissue
disease characterised by autoimmunity, vascular abnormal-
ities, and fibrosis via accumulation of extracellular matrix
(ECM) proteins. Uncontrolled fibrosis progression often
results in dysfunction of the affected organs and consequently
leads to premature death in SSc patients [39]. The role of
miRNA has also been demonstrated in SSc pathogenesis. It
has been shown that the family of miRNA-29 plays a pivotal
role in SSc skin fibrosis by targeting collagen expression [19,
20]. In addition, we have shown that SSc fibroblasts are able to
reverse fibrotic phenotype following miRNA-29 transfection.
We found that miRNA-29 can modulate its novel target
gene, TAB1, and that it downregulates tissue inhibitor of
metalloproteinases-1 (TIMP-1) expression as a result of TAB1
degradation [21]. Similarly, transfection of miRNA-30a-3p
in IFN-𝛾-activated SSc fibroblasts decreases synthesis of B
cell-activating factor (BAFF) [40]. BAFF plays a central
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role in the survival and homeostasis of B cells and plasma
cells. Autoreactive B cells are strongly dependent on BAFF
presence and the increased level of BAFF correlates with high
autoantibody titers andwith disease activity in SSc.Therefore,
miRNA-30 targeting BAFF expression could be used in SSc
therapy. In addition, 5󸀠-AZA-treated SSc T cell has shown
increased CD11a expression, whereas 5󸀠-AZA-treated SSc T
cells cocultured with either B cells or fibroblasts resulted in
increased production of IgG or COL1A2, respectively [41].
These data suggest that demethylation of CD11a regulatory
elements and subsequentCD11a overexpression inT cellsmay
mediate immunological abnormalities and fibrotic processes
in SSc. Therapies which reduce CD11a due to specific DNA
methylation are needed in SSc. On the contrary, our latest
results have shown that 5󸀠-AZA-treated fibroblasts decreased
expression of collagen and upregulated the miRNA-135b
expression level. miRNA-135b targets STAT6 and attenuates
the IL-13-induced collagen expression. This indicates that
specific targeting DNA methylation may represent a novel
therapeutic approach for the treatment of SSc.
Another hallmark of SSc is perivascular infiltration of
immune cells, mainly monocytes, which are the first immune
cells to infiltrate the SSc skin. The results from our group
demonstrated that circulating monocytes from SSc patients
contribute to the imbalance between TIMP-1 and MMPs
and to increased profibrotic IL-6 production upon TLR8
agonist stimulation (ssRNA) [42–44]. Interestingly, we have
also shown that epigenetic modification induced by DZNep
(histone methyltransferases) or apicidin (inhibitor of his-
tone acetylases) in SSc monocytes can modulate TIMP-1
expression and subsequently fibroblasts transdifferentiation
[44]. Another study has shown that global H4 but not H3
acetylation of SSc B cells was positively correlated with
disease activity and that the expression of HDAC2 protein
was negatively correlatedwith skin thickness [45].This clearly
indicates that epigenetic alteration plays an important role in
the pathogenesis of SSc.
8. Psoriatic Arthritis
Psoriatic Arthritis (PsA) is a chronic inflammatory skin
disease with unknown etiology. The interactions between
genetics and the environmental factors in PsA are still
not well defined. The disease is characterised by abnor-
mal proliferation and differentiation of keratinocytes. In
addition, infiltration of immune cells which secrete high
level of various immune-regulated inflammatory cytokines
and chemokines is observed in PsA. Recently, imbalance in
epigenetic networks has been indicated to be an important
element in psoriasis development. Several studies have shown
that differentially expressed miRNAs levels play a role in
psoriasis pathogenesis. In particular, it has been reported
that miRNA-203 expression is downregulated in psoriatic
lesion. Based on bioinformatic analysis, miRNA-203 targets
gene suppressors of cytokine signalling 3 (SOC3). SOC3
is involved in negative regulation of the IL-6 transcription
factor STAT3. Furthermore, miRNA-203 directly targets
TNF-𝛼 and proinflammatory IL-24 in primary keratinocytes
[46]. Another group identified that miRNA-146a is also
dysregulated in psoriatic lesions. miRNA-146a targets the
TNF receptor-associated factor 6 (TRAF6) and the IL-1
receptor-associated kinase 1 (IRAK1). Activation of IRAK1
triggers the production of TNF-𝛼, IL-6, IL-8, and IL-1𝛽. Xia et
al. also found that the increased level of miRNA-146a is posi-
tively correlated with the Psoriasis Symptom Inventory (PSI)
score [47]. In contrast, the addition of anti-TNF-𝛼 blocking
antibody reduced the level ofmiRNA-146a in patients’ serum.
These data suggest that overexpression of miRNA-203 and
miRNA-146a may be useful in repression of the immune-
mediated inflammation process and may provide potential
therapeutic strategy in psoriasis pathogenesis. Another study
reported that the DNA methylation pattern is changed in
psoriatic skin in comparison to normal tissue. They showed
strong correlation between S100 Calcium Binding Protein A9
(S100A9) andDNAmethylation signature of psoriasis patient
samples fallowing phototherapy [48]. S100A9 is a calcium
binding protein which plays a prominent role in regulation of
inflammatory processes and immune response. Also, Gervin
et al. have demonstrated that monozygotic twins (MT) have a
differentmethylation pattern between an unaffected twin and
a twin suffering for PsA [8]. They showed the differences in
DNAmethylation pattern of proinflammatory TNF-𝛼 ligand
11 also known as the receptor activator of nuclear factor
kappa-B ligand (RANKL) in MZ twins. Moreover, DNA
methylation signature of the arachidonate 5-lipoxygenase-
activating protein (ALOX5AP) gene is altered in psoriatic
MZ twin. ALOX5AP is involved in catalysis of arachidonic
acid regulating inflammation via leukotrienes production.
Another study has shown that 50% of CpG islands in the
promoter region of p16 gene are hypermethylated in psoriatic
epidermis and correlated with diseases activity [49]. p16 is
an antiapoptotic protein that supports the concept of an
abnormal mechanism of hyperproliferative skin diseases.
Abnormal expression of HATs and HDACs regulating gene
expression has been also observed in PsA. Indeed, Ham et al.
have shown that the promoter region of HDAC-6 is hyper-
methylated in naive CD4+ T cells in patients. Furthermore,
the level of HDAC-1 in skin samples and PBMCs from PsA
patients is increased compared to healthy subjects [50, 51].
These findings implicate that novel therapy for PsA should be
also supplemented with agents altering the abnormal histone
modification pattern.
9. Systemic Lupus Erythematosus
Theetiology of Systemic Lupus Erythematosus (SLE) remains
to be elucidated; however it is an autoimmune disorder
with clear links to the innate and adaptive immune systems.
Environmental triggers may initiate the disease on a genetic
susceptibility background. SLE is a multiorgan disorder in
which there are autoantibodies toDNA that are not only diag-
nostic of the disease but also pivotal in disease pathogenesis.
It was as early as 1990 that methylation abnormalities
were first described in SLE T cells. The most convincing
evidence comes from the fact that procainamide and 5󸀠-AZA
(both hypomethylating drugs) treated CD4+ T cells cause a
lupus-like disease in mice [52]. This suggests a critical role
of hypomethylation in T cells in mediating SLE [52]. It was
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suggested that decreased Ras signalling is involved also in
DNA hypomethylation in T cells [53]. Other studies have
suggested that growth arrest and DNA damage-induced gene
45𝛼 (GADD45𝛼) are associated with DNA hypomethylation
in SLE [54]. In further support of this it was demonstrated
that increased oxidative stress in T cell in SLE may alter the
expression of various proteins but also force downregula-
tion of DNMT1 expression and thus hypomethylation [55].
Indeed, adoptive transfer of T cells modified by oxidative
stress into syngeneic mice resulted in lupus-like disease with
reduced methylation [56]. A study found that isolated T cells
from SLE patients were globally hypomethylated. The genes
methylated include CD11a and CD70 [57]. CD11a of course
forms lymphocyte function-associated antigen 1 and would
be important in immune responses. The X chromosome in
women with lupus is hypomethylated suggesting a reason for
the preponderance in females [58]. A large scale genomewide
DNA methylation study in isolated CD4+ T cells from lupus
patients found 236 hypomethylated CG sites. Enrichment
of genes associated with apoptosis was found. A further
study of DNA methylation in isolated T cells found that
a large amount of interferon regulated genes is methylated
differently. The authors suggest that there is an epigenetic
alteration of interferon genes which explains the interferon
response in SLE [59]. Similarly, it has been found that inter-
feron regulated genes in CD4+ T cells of SLE patients that
had quiescent disease are hypomethylated, which suggests
that they are poised “to trigger” [60]. Recently, a study of
SLE patients has demonstrated that altered DNAmethylation
pattern of interferon genes is associated with production of
autoantibodies characterising SLE [61]. As well as T cells
playing a critical role, B cells have also been described to
be involved in SLE pathogenesis. Indeed, hypomethylation
of SLE B cells has been described and blocking IL-6 with
a monoclonal antibody restores B cell methylation levels.
These data suggest that IL-6 is driving B cell alterations [62].
Interestingly, miRNA-155 targets Activation Induced Cyti-
dine Deaminase (AICDA) which is critical in B cell develop-
ment. It has been demonstrated that AICDA is dysregulated
in SLE. miRNA-29b appears to be overexpressed in SLE
CD4+ T cells and indirectly regulates hypomethylation by
targeting DNMT1. DMNT1 is an enzyme which is important
in DNA methylation [63]. The important negative regulators
of TLR signalling are miRNA-146a and miRNA-29 which are
dysregulated in SLE [64, 65]. It was also further shown that
miRNA-21 additionally targets DNMT1 in SLE CD4+ T cells
[66]. Interestingly, the authors demonstrated that targets of
miRNA-146 included the interferon regulatory factor 5 and
STAT1, a downstream target of IFN activation, and these
are indeed dysregulated in SLE. A great study demonstrated
that miRNA-3148 affects the stability and regulation of TLR7
[67]. TLR7 is the receptor for RNA and this is clearly
important in SLE and is highly expressed on dendritic cells
and may link RNA, TLR, and miRNAs together. In T cells
miRNA-31 has also been found to be dysregulated in T
cells and this dysregulation is associated with the impaired
production of IL-2, a critical T cell growth factor [68]. It
is clear that a multitude of miRNAs are dysregulated in
SLE; therefore cell-free miRNAs have recently emerged as
noninvasive biomarkers [69]. miRNA-146 and miRNA-155
have been found to be a possible biomarker in SLE derived
fromurinary sediment [69]. Abnormal histonemodifications
have also been described in SLE. It has been reported that
in SLE patients there is a global histone hypoacetylation
due to downregulation of Ezh2 enzyme. Ezh2 is involved in
histone methylation [70]. The epigenetic modifying enzyme
Ezh2 has been also found to be downregulated in the SLE
T cells and this is one of the enzymes that methylate the
histones [70]. Ezh2 has been also shown to be regulating the
expression of the transcription factor STAT5 to epigenetically
repress the immunoglobulin K chain complex, critical in B
cell lineages [71]. Using the lupus-prone mouse model, it
was found in the isolated T cells from this model that the
HDACs were dysregulated suggestive of the mechanism of
altered histone methylation [72]. Histone H3 trimethylation
has also been described to be altered in SLE [73]. The major
histone modifications which are implicated in SLE include
methylation and acetylation and both are reversible. It has
been shown in the lupus mouse model that introduction of
TSA (a broad spectrum HDAC inhibitor) reduced IL-6 level
and proteinuria [74]. CD70 is also elevated on CD4+ T cells
from SLE patients and associated with higher dimethylated
H3 lysine 4 in these patients [75].
10. Sjogren’s Syndrome
Sjogren’s syndrome (SS) is an autoimmune disorder that
affects the lacrimal and salivary glands, causing hypofunction
which leads to dry eyes and dry mouth (xerostomia). There
are a large prominent lymphocytic infiltrate in the salivary
glands and also specific autoantibodies in the disease too.
Patients with SS have a 20–40-fold increased risk of devel-
oping lymphoma.There are both associations with the innate
and adaptive immune systems. Because the innate immune
system has been heavily implicated in disease pathogenesis
many studies have focussed on this system. One of the first
miRNAs that has been shown to be dysregulated is miRNA-
146a [76]. miRNA-146a has been found to be elevated in
PBMCs of SS patients; however, the precise cell type of the
PBMCs has not been confirmed [76, 77]. More importantly,
Pauley et al. have shown that enhanced miRNA-16a levels
in monocytes lead to increased phagocytosis in functional
assays. This could represent a mechanism to help restore
the altered phagocytosis seen in the disease. A follow-up
study confirmed the increased miRNA-146a levels and the
decreased target gene IRAK1 levels in PBMCs [78]. Using the
minor salivary gland and whole miRNA arrays, a number of
differentially regulated miRNAs in salivary glands from SS
patients was found; however, their targets and the functional
consequences of the differentially expressed miRNAs are still
unknown [79]. A very interesting recent study showed that
the SS related antigen B promotes global miRNA processing
[80].
It has been recently shown that salivary gland epithelial
cells are globally hypomethylated compared to controls [81].
A very interesting observation was that the global gland
epithelial cells hypomethylation may be attributed to B cells
as treatment with the B cell depleting antibody rituximab
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had more methylation. In isolated T cells from SS patients it
has been found that they have lower FoxP3 expression levels,
both mRNA and protein levels, and that this is associated
with hypermethylation of the promoter region [82]. This
observation could explain the reduced number of T reg cells
in SS. A recent genomewide methylation study in isolated
CD4+ T helper cells identified a multitude of genes that are
differentially regulated in SS. The interferon pathways genes
STAT1, IFI44L, and USP18 are all hypomethylated [83].
11. Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a chronic and common
inflammatory rheumatic disease characterised by new bone
formation, ankyloses, and inflammation of the hips and spine.
miRNA-16 andmiRNA-221 are aberrantly expressed in T cells
[84]. A functional SNP variant in miRNA-196a was found
to be associated with Behcet’s disease but not AS [85]. A
recent study in AS demonstrated that miRNA-124 is elevated
in peripheral blood cell of AS patients. miRNA-124 targets
Anthrax Toxin Receptor 2 (ANTXR2) which is associated
with risk of AS development [86]. Interestingly, inhibition
of ANTXR2 by miR-mimics in vitro caused autophagy and
subsequently protects T cells from apoptosis conferring
advantage. Niu et al. have looked at common polymorphism
in miRNA-146a associated with AS. However, no polymor-
phism was associated [87]. In AS, T cells are proposed to play
a role; however, their precise role is unclear. It was shown that
FoxP3 positive T cells are elevated in the inflamed joint in
AS and that the FoxP3 locus is demethylated. This suggests
that epigenetic mechanisms control FoxP3 expression [88].
Recently, in serum it was found that there were higher levels
of SOCS1 methylation as compared to healthy controls and
higher levels of SOCS methylation associated with higher
IL-6 levels [89]. SOCS1 is the negative regulator of STAT1
signalling which is initiated after IL-6 stimulation; thus a
reduction in the negative regulator of STAT1 would lead to
unperturbed STAT1 signalling.
Reduced HDAC and HAT activities have been described
in AS in PBMCs compared to controls [90]. The functional
relevance of this is unknown because the balance between
these two enzymes was not different. Furthermore, after anti-
TNF-𝛼 therapy HAT activity increased in AS patients, with
a clear increase in the HAT/HDAC balance [91]. Only one
manuscript has demonstrated the altered histonemethylation
in CD4+ T cells in AS. In particular, it has been shown that
specific AS SNP genotype has an altered histonemodification
profile and possibly alters binding to important transcription
factors critical in the disease [92].
12. Giant Cell Arteritis
Giant Cell Arteritis (GCA) is a systemic autoimmune dis-
ease primarily affecting the elderly. It is characterised by
inflammation of the large- and medium-sized arteries. GCA
typically affects the temporal arteries. One of the most
devastating features of the disease can be acute visual loss
and patients can be present with ischaemic complications of
the disease. One study found 853 hypomethylated genes in
temporal arteries from GCA patients compared to controls.
Many of these hypomethylated genes were associated with
both Th1 and Th17 cells [93]. DNA methylation was also
found to be altered in nuclear factor of activated T cells
(NFAT), which was confirmed to be altered by immuno-
histochemistry [93]. NFAT is a critical factor mediating
production of proinflammatory cytokines including IL-23.
Thus, methylation regulation of NFAT may be crucial in
driving the activation of Th17 cells in GCA. Only one report
of dysregulated miRNA has been published in GCA and
this study found that miRNA-21 was dysregulated in GCA
temporal biopsies [94]. miRNA-21 was overexpressed in the
biopsies and this appears to be tissue specific, as the use of
PBMCs derived from the same donorswhen compared across
groups demonstrated no difference. These data suggest that
the increase of miRNA-21 level is tissue specific [94]. To this
day only, a handful of studies have looked at the epigenome
in GCA and this is a rich area for research. Epigenetics could
underpin the variable clinical course of the disease.
13. Conclusions
It is now clear that in all the autoimmune rheumatic diseases
there are various epigenetic aberrations (Figure 1). Each
specific disease is likely to have its own epigenetic signature;
for example, RA appears to be hypomethylated whereas in
SSc the fibroblasts, at least, appear hypermethylated. Thus,
different approaches to treatmentwill bewarranted. It is likely
that in the hypermethylated state in SSc the use of decitabine
may be useful but in RA where the fibroblasts are already
hypermethylated this would exacerbate the situation.Histone
modifications are also likely to differ in different diseases and
any drugs that target specific histone modifications must be
used with knowledge of the precise histone modifications
occurring in that particular setting. This will be critical in
the treatment regime. Noncoding RNAs like miRNAs are
now emerging as excellent druggable targets; however, issues
regarding their stability and targeting in vivo still remain
unclear. How do we get the right miR-mimic or antagomiR
to the precise tissue? This is an active area of research and it
is already bearing fruit with the use of aptamers. Epigenetic
therapies are now coming to the fore and the use of the first
miRNA therapy in HCV appears to be a success.
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